A Trial of Doxorubicin/Cyclophosphamide (AC), Docetaxel (D), and Alternating AC and D for Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Neoplasm Metastasis
Interventions: DRUG: AC (ADM 40mg/m2+CPA 500mg/m2) q21 days x 6 cycles|DRUG: Docetaxel 60mg/m2 every 21 days for 6 cycles|DRUG: AC and Docetaxel 60mg/m2 alternately q21 days for 6 cycles
Sponsor: Japan Clinical Oncology Group
Collaborators: Ministry of Health, Labour and Welfare, Japan